SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurex Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wendell morris who wrote (423)3/14/1998 11:57:00 AM
From: Cody Goebel   of 449
 
Wendell, I thought you would have covered when NXCO dipped back to the 18s or so. I have nothing against short selling but I think you are barking up the wrong tree here. Shorting biotech stocks is probably more lucrative than holding them on average but NXCO is a particularly interesting time in its development. First, it is going to see revenues from its first approved drug this quarter--Corlopam--and these could even exceed expectations. Secondly, it just reported very good news on its lead candidate. Sure its market cap is about $400mm but chronic pain and other uses for Ziconotide are $1 billion plus market, from what I understand. I wish you luck in your investing and of course hope you are wrong here, but there may be better short candidates than this one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News